Viking Therapeutics continued producing eye-catching obesity data with its dual GLP-1/GIP agonist VK2735 at the ObesityWeek 2024 meeting in San Antonio, with its oral formulation showing class-leading weight loss results in updated findings from a Phase I multiple-ascending-dose (MAD) study. Meanwhile, CinFina Pharma reported weight reduction and tolerability for a pair of Phase I obesity candidates with next-generation mechanisms of action.
Viking Excites With Latest Oral VK2735 Weight Loss Data
CinFina Advances Next-Generation Obesity Drugs
Viking’s dual GLP-1/GIP agonist VK2735 continues to make headlines for strong efficacy and tolerability with oral and injectable formulations. CinFina reports progress with two new MOAs.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus